US Patent

US8227462 — Pyrrolidine-1,2-dicarboxamide derivatives

Method of Use · Assigned to Novartis AG · Expires 2033-04-29 · 7y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a compound of formula (I) and its salts, used in compositions for treating diseases alleviated by inhibiting phosphatidylinositol 3-kinase.

USPTO Abstract

The present invention relates to a compound of formula (I) or a salt thereof, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.

Drugs covered by this patent

Piqray (alpelisib) · Novartis

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3809`	—	Piqray
`U-3809`	—	Piqray
`U-3809`	—	Piqray

Patent Metadata

Patent number: US8227462
Jurisdiction: US
Classification: Method of Use
Expires: 2033-04-29
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.